ArticleMolecular medicine reports2016
β-Catenin signaling pathway regulates cisplatin resistance in lung adenocarcinoma cells by upregulating Bcl-xl.
Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- miR-145-5p/CAMSAP2 axis modulates cisplatin sensitivity in non-small cell lung cancer.Cancer cell international · 2026Article
- Dual-targeted N-PMIMaterials today. Bio · 2025Article
- Senataxin regulates cisplatin resistance through an R-loop-mediated mechanism in HPV-associated head and neck cancer.iScience · 2025Article
- β-catenin as a key regulator of the cisplatin response in tumor cells.Clinical and experimental medicine · 2025Review
- Article
- Article
- Design, synthesis and pharmacological evaluation of 1,2,3,4-tetrahydrobenzofuro[2,3-Acta pharmaceutica Sinica. B · 2025Article
- Zinc Oxide Nanoparticles and Cancer Chemotherapy: Helpful Tools for Enhancing Chemo-sensitivity and Reducing Side Effects?Biological trace element research · 2024Review
- Natural compounds: Wnt pathway inhibitors with therapeutic potential in lung cancer.Frontiers in pharmacology · 2023Review
- A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer.Computational and structural biotechnology journal · 2023Article
- Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.Cell death & disease · 2021Article
- Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.International journal of molecular sciences · 2021Article
- Mechanisms of resistance to chemotherapy in non-small cell lung cancer.Archives of pharmacal research · 2021Review
- The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies.Frontiers in cell and developmental biology · 2021Review
- Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Negative Effect of Reduced NME1 Expression on Recurrence-Free Survival in Early Stage Non-Small Cell Lung Cancer.Journal of clinical medicine · 2020Article
- Emetine Synergizes with Cisplatin to Enhance Anti-Cancer Efficacy against Lung Cancer Cells.International journal of molecular sciences · 2019Article
- Mechanistic Study of TTF-1 Modulation of Cellular Sensitivity to Cisplatin.Scientific reports · 2019Article
- Role of β-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2018Article
- microRNA-1236-3p Regulates DDP Resistance in Lung Cancer Cells.Open medicine (Warsaw, Poland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Wnt/β‑catenin signaling pathway has been reported to regulate cisplatin resistance in several types of cancer cell. The present study aimed to investigate the role and underlying mechanism of Wnt/β‑catenin signaling in cisplatin resistance of lung adenocarcinoma cells. Wild‑type and cisplatin‑resistant A549 human lung adenocarcinoma cells (A549/WT and A549/CDDP, respectively) were cultured in vitro and exposed to different cisplatin concentrations. Cells were incubated with 10 mM lithium chloride (LiCl) to activate β‑catenin signaling. Cell proliferation was determined using the MTS assay. Cell apoptosis was evaluated using Annexin V/propidium iodide double staining, followed by flow cytometry. β‑catenin was knocked down using small interfering RNA (siRNA). The intracellular distribution of β‑catenin was determined by immunocytochemistry, and the mRNA and protein expressions of target genes were examined by reverse transcription‑quantitative polymerase chain reaction and western blotting, respectively. β‑catenin and B‑cell lymphoma‑extra large (Bcl‑xl) were significantly upregulated in A549/CDDP cells compared with A549/WT cells (P<0.05). LiCl reduced the sensitivity of A549/WT cells to cisplatin (P<0.01); and upregulated, increased phosphorylation (P<0.05) and enhanced nuclear translocation of β‑catenin. LiCl also significantly elevated the mRNA and protein expression levels of Bcl‑xl (P<0.05). Notably, silencing of β‑catenin with siRNA decreased the mRNA and protein expression of Bcl‑xl, and sensitized A549/WT cells to cisplatin (P<0.01). The findings of the current study suggest that upregulation of β‑catenin signaling may contribute to cisplatin resistance in lung adenocarcinoma cells by upregulating Bcl‑xl. Therefore, molecular targeting of Wnt/β‑catenin signaling may sensitize lung cancer cells to cisplatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.